Effective confirmation test of moisturizer for the dermatopathy of patients receiving EGFR(epidermal growth factor receptor)inhibitor

Effective confirmation test of moisturizer for the dermatopathy of patients receiving EGFR(epidermal growth factor receptor)inhibitor - Effective confirmation test of moisturizer for the dermatopathy of patients receiving EGFR inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034433

Enrollment

Registered

2018-10-10

Start date

2018-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients receiving EGFR inhibitor

Interventions

Use the test moisturizer in combination with treatment at more than twice a day Continue a convientional product(ethical drug)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Lung cancer patients with positive EGFR gene variation Patients receiving gefitinib(Iressa),erlotinib(Tarceva)and afatinib(Giotrif) Patients aged of 20 to 90 at the time of enrollment The sex does not matter After receiving sufficient explanation for participation in this research, after sufficient understanding,the patient himself or herself

Exclusion criteria

Exclusion criteria: Person who experienced skin symptoms such as contact dermatitis due to the ingredients of this research item and similar ingredients Person who cannot evaluate it by the QOL method by himself or herself Person who cannot use the moisturizer by himself or herself In addiction,parson who the research staff judged inappropriate as subjects

Design outcomes

Primary

Measure	Time frame
Improvement of skin dryness(skin findings)	—

Secondary

Measure	Time frame
Skin physiological verification(changes in skin measurement value and cytokine in epidermal horny layer) Changes in stratum corneum water content,epidermal water transpiration amount,sebum quantity Improvement of QOL and feeling of use of this research product by questionnaire	—

Countries

Japan

Contacts

Public ContactAika Okuno

Takatsuki red cross hospital Dermatology

aika0119@kuhp.kyoto-u.ac.jp0726-96-0571

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026